MedCity News
JUNE 25, 2025
Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said.
World of DTC Marketing
JULY 1, 2025
For decades, the image of pharmaceutical direct-to-consumer (DTC) marketing has been defined by glossy TV commercials: smiling patients, soft music, lengthy lists of side effects spoken at a rapid pace, and vague promises of a better life. But that era is quickly becoming obsolete. We’re entering a new era of pharma DTC marketing—one grounded not in big ad budgets and prime-time placement, but in trust, transparency, and easy-to-understand health information.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 2, 2025
Chinese regulators have approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer.
PharmaVoice
JULY 10, 2025
ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
JUNE 8, 2025
Arkansas became the first state to pass a law banning pharmacy benefit managers from owning pharmacies, aiming to curb their market power and reduce drug costs. But major PBMs like CVS and Express Scripts are suing, claiming the law is unconstitutional. The post Why CVS, Express Scripts Are Suing Over the Arkansas PBM Law appeared first on MedCity News.
MedCity News
JUNE 23, 2025
In Phase 1/2 results for 12 patients at least one year after receiving the cell therapy, zimislecel, Vertex Pharmaceuticals reported all participants achieved blood glucose in the target range and 10 of the 12 were free of exogenous insulin as of the data cutoff. Vertex expects to complete enrollment in the pivotal portion of the study this summer, paving the way for potential regulatory submissions next year.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JANUARY 30, 2025
Phase 2 data for Cargo Therapeutics CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025. The post Safety Risk Sinks Cargo Therapeutics Cancer Cell Therapy Prospect, Leading to 50% Staff Cut appeared first on MedCity News.
MedCity News
JANUARY 15, 2025
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The post Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings appeared first on MedCity News.
MedCity News
JANUARY 31, 2025
We are living in a moment when many realize that collaboration yields better, faster and more affordable advances. Open source also enables the potential for bigger profits and revenue. Whats in reach: a small amount of money paid for treatments across millions of people, rather than expensive lifesaving treatments only for the few who can afford them.
MedCity News
FEBRUARY 4, 2025
VR allows learners to actually see the virtual germs responsible for causing infections and spreading disease, which could otherwise only be seen under a microscope. The technology also heightens users’ senses, drawing their attention to things they would be unable to see in traditional learning environments. The post The Future of Training: How Virtual Reality Can Protect Clinicians from Healthcare-associated Infections appeared first on MedCity News.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
MedCity News
JANUARY 8, 2025
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement. The post Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagships Valo Health appeared first on MedCity News.
MedCity News
JANUARY 2, 2025
Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries. The post AI Developers Need Real-World Data and Atropos Health Is Stepping Up to Help appeared first on MedCity News.
MedCity News
JANUARY 8, 2025
Galapagos said the planned business separation will leave the legacy company free to focus on developing cell therapies for cancer. An accompanying corporate restructuring will shave Galapagoss headcount by 40%. The post Galapagos Keeps Focus on Cancer Cell Therapy, Spins Out Rest of Biz Into NewCo Backed by 2.4B appeared first on MedCity News.
MedCity News
JUNE 24, 2025
Healthcare doesn’t reward shortcuts. It rewards outcomes. AI will play a critical role in shaping those outcomes — but only if leaders measure what truly matters. The best AI implementations elevate expertise, improve quality and create space for innovation. The post How Smarter Metrics Can Unlock AI’s Potential in Healthcare appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
FEBRUARY 17, 2025
Mercks implementation of artificial intelligence in drug research includes analyzing years of existing Merck clinical data to help identify which drugs and drug combinations to pursue. But Merck executive Matt Studney said AI is tool to help, not replace humans. The post Merck Is Embracing AI, But We Always Have a Human in the Loop, Exec Says appeared first on MedCity News.
MedCity News
JULY 8, 2025
Demonstrating the clinical utility and cost-effectiveness of innovative blood-based biomarker tests can help pave the way for making timely AD diagnosis and proactive care the norm. The post Broadening Biomarker Validation for Alzheimer’s Disease Diagnosis Globally appeared first on MedCity News.
MedCity News
MAY 2, 2025
AI addresses the disconnect between recommended guidelines and action by increasing engagement with personalized, actionable education and updates at appropriate times, The post AI in Clinical Settings: Balancing Innovation, Patient Care, and Personalized Medicine appeared first on MedCity News.
MedCity News
APRIL 24, 2025
The time to innovate is now. By embracing transformative solutions, insurers and employers can not only address systemic challenges but also create a future where healthcare is equitable and sustainable. The post How Health Insurers Are Embracing Technology to Serve Real People appeared first on MedCity News.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
JANUARY 28, 2025
Quibims technology applies artificial intelligence analysis to medical images to detect biomarkers. Hospitals and biopharma companies are among the startups customers, using its technology to analyze images to detect disease and guide clinical trial enrollment. The post Medtech Startup Quibim Corrals $50M to Advance AI Analysis in Medical Imaging appeared first on MedCity News.
MedCity News
MAY 8, 2025
Trust in the U.S. healthcare system is eroding, but experts say rebuilding it is possible. They say this will require both payers and providers to prioritize empathy, transparency and personalized communication. The post Americans Trust in the Healthcare System Is Plummeting. How Can It Be Repaired? appeared first on MedCity News.
MedCity News
FEBRUARY 2, 2025
Investors showed appetite for Metseras IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined. The post Metseras IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s appeared first on MedCity News.
MedCity News
APRIL 14, 2025
The decade ahead will test our healthcare system like never before. But within these challenges lies an opportunity to create a more accessible, effective, and sustainable healthcare system if we dare to innovate and adapt to the changing landscape. The post How Technology and Value-Based Models Will Reshape Healthcare by 2035 appeared first on MedCity News.
MedCity News
APRIL 18, 2025
Robert F. Kennedy Jr.s rise to become secretary of the Department of Health and Human Services has some concerned that anti-vaccine policies are coming. If the nations top public health agency pulls support of vaccination, other healthcare stakeholders will need to step up to fill the vaccine messaging void. The post How the Health Sector Can Change Vaccine Messaging Amid Rising Anti-Vaccine Sentiment appeared first on MedCity News.
MedCity News
MARCH 9, 2025
Healthcare organizations are starting to implement AI agents autonomous, task-specific systems designed to perform functions with little or no human intervention. While initial adoption is focused mainly on non-clinical areas like scheduling and prior authorizations, experts predict that AI agents could eventually play a role in clinical decision-making, provided they meet rigorous safety and reliability standards.
MedCity News
JANUARY 17, 2025
With technology advancements specifically in the field of AI, there is a clear line of sight in making it mainstream. Here are some of the ways AI is helping to accelerate the adoption of PM. The post Precision Medicine: Becoming More Real With AI? appeared first on MedCity News.
MedCity News
JANUARY 9, 2025
Verdiva Bios once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences. The post Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
JANUARY 9, 2025
AI offers a number of immediate opportunities for pharmacies to change their operation through intelligent automation, freeing up pharmacists to provide their patient population with higher-value services like patient counseling and medication management. The post What AI Can Do for Pharmacist Burnout appeared first on MedCity News.
MedCity News
APRIL 13, 2025
At Medicarians 2025, MedCity News Editor-in-Chief Arundhati Parmar explored the state of AgeTech venture capital with three investors. The panelists agreed that despite growing clear opportunities, the AgeTech market currently lacks the dedicated funding, proven business models and major success stories needed for it to take off. The post Where Does AgeTech Investment Stand?
MedCity News
JANUARY 8, 2025
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO markets return to normal levels. The post Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More appeared first on MedCity News.
MedCity News
FEBRUARY 28, 2025
To bridge the gap between invasive and non-invasive technologies, nanoscale materials, such as biocompatible nanoparticles, provide a promising alternative, allowing us to design materials at the scale of cellular systems and structures. The post Biocompatible Nanoparticles: Tiny Antennae with Huge Potential for Brain-Computer Interfaces appeared first on MedCity News.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
336 
Let's personalize your content